The Claim
In adults with obesity, the correlation coefficient between total weight loss and lean mass loss is lower with semaglutide (R=0.55) than with diet and lifestyle interventions (R=0.93), indicating a weaker linear relationship between these two outcomes under semaglutide treatment.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In adults with obesity, losing weight with semaglutide is less closely tied to losing muscle mass compared to losing weight with diet and lifestyle changes alone.
See the scientific wording
In adults with obesity, the relationship between total weight loss and lean mass loss is weaker with semaglutide (R=0.55) than with diet and lifestyle interventions (R=0.93), indicating that semaglutide leads to a less predictable loss of muscle relative to overall weight loss.
Semaglutide causes the body to lose weight by reducing appetite and fat stores, but it also makes muscle breakdown less controlled by how much food a person eats. When someone eats less protein, their muscles break down more easily under semaglutide, and older adults or women lose more muscle because their bodies naturally rebuild muscle slower. This makes muscle loss unpredictable compared to dieting alone, where muscle loss follows total weight loss more closely.
What the research says
1 studyWhen people lose weight with semaglutide, the amount of muscle they lose doesn’t reliably match how much total weight they lose — unlike with dieting, where muscle loss is much more predictable. The study found this difference clearly in the numbers.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.